Full history for every metric is available with a Kvantra account
Kindred Biosciences, Inc. (KIN)
Key financial summary
Financials in USD| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | ||
|---|---|---|---|---|---|---|---|
| Total revenue | $m | 0 | 0 | 0 | 2 | 4 | 42 |
| Operating profit | $m | -20 | |||||
| Net profit | $m | -27 | -22 | -31 | -50 | -61 | -24 |
| EPS reported | $ | -0.60 | |||||
| Operating cashflow per share | $ | -0.25 | |||||
| Capex per share | $ | 0.09 | |||||
| FCF per share | $ | -0.34 | |||||
| Free cash flow | $m | -13 | |||||
| Net debt | $m | -38 | |||||
| Book value equity | $m | 67 | |||||
| Book value per share | $ | 1.72 | |||||
| Number of shares | m | 39.29 | |||||
| DPS (TTM paid) | $ | 0.00 |
Financial summary
Financials in USD| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | ||
|---|---|---|---|---|---|---|---|
| Value | |||||||
| P/E TTM | x | - | |||||
| P/B LTM | x | 2.51 | |||||
| P/S LTM | x | 4.02 | |||||
| P/FCF LTM | x | -12.55 | |||||
| EV/EBITDA LTM | x | -11.65 | |||||
| EV/Sales LTM | x | 4.23 | |||||
| Earnings Yield LTM | % | -13.95% | |||||
| FCF Yield | % | -7.97% | |||||
| Quality | |||||||
| ROE | % | -35.01% | |||||
| ROIC | % | -21.98% | |||||
| Operating margin | % | -47.36% | |||||
| Gross margin | % | 89.03% | |||||
| FCF/Sales | % | -32.01% | |||||
| Growth and momentum | |||||||
| EPS Growth YoY | % | - | |||||
| Sales Growth YoY | % | +890.70% | |||||
| Net Income Growth YoY | % | - | |||||
| FCF Growth | % | - | |||||
| Operating Profit Growth | % | - | |||||
| Dividend and capital structure | |||||||
| Dividend Yield | % | 0.00% | |||||
| Dividend Growth | % | 0.00% | |||||
| Payout Ratio | % | 0.00% | |||||
| FCF/Debt | x | -0.66 | |||||
| Net Debt/EBITDA | x | -0.58 | |||||
| EBIT/Net interest | x | -10.92 | |||||
| Net debt/market cap | % | -22.41% | |||||
| Net debt/Equity | x | -0.56 | |||||
| Gross debt/equity | x | 0.30 | |||||
Company overview
Kindred Biosciences, Inc. is a biopharmaceutical firm dedicated to the advancement of biological therapies specifically for companion animals. The company maintains an extensive pipeline of innovative biologics, spanning diverse therapeutic categories, underpinned by a robust intellectual property portfolio. Key development programs include treatments for canine atopic dermatitis, utilizing both interleukin-31 and interleukin-4R, as well as KIND-030 to combat parvovirus in dogs. Additionally, KIND-510a targets non-regenerative anemia in cats, while an anti-TNF antibody is being developed for canine inflammatory bowel disease. Further candidates within its biologics portfolio are also under investigation. Established in 2012, Kindred Biosciences is headquartered in Burlingame, California.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
Kindred Biosciences, Inc. (KIN)
Kindred Biosciences, Inc. is a biopharmaceutical firm dedicated to the advancement of biological therapies specifically for companion animals. The company maintains an extensive pipeline of innovative biologics, spanning diverse therapeutic categories, underpinned by a robust intellectual property portfolio. Key development programs include treatments for canine atopic dermatitis, utilizing both interleukin-31 and interleukin-4R, as well as KIND-030 to combat parvovirus in dogs. Additionally, KIND-510a targets non-regenerative anemia in cats, while an anti-TNF antibody is being developed for canine inflammatory bowel disease. Further candidates within its biologics portfolio are also under investigation. Established in 2012, Kindred Biosciences is headquartered in Burlingame, California.
Unlock all fundamental data
Sign up for FreeUnlock all fundamental data
Sign up for Free